

**Isoform-Selective HDAC Inhibition for the Treatment of Lupus Nephritis**

**Nicole L. Regna**

Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in  
partial fulfillment of the requirements for the degree of

Doctor of Philosophy  
In  
Biomedical and Veterinary Sciences

Christopher M. Reilly, Chair  
David L. Caudell  
Yong W. Lee  
Rujuan Dai

June 3, 2014  
Blacksburg, VA

Keywords: Histone deacetylase, T cells, B cells, systemic lupus erythematosus

Copyright © 2014 Nicole Regna

**ELSEVIER LICENSE  
TERMS AND CONDITIONS**

Jun 16, 2014

This is a License Agreement between Nicole Regna ("You") and Elsevier ("Elsevier") provided by

Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and

conditions provided by Elsevier, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

**Supplier** Elsevier Limited

The Boulevard, Langford Lane  
Kidlington, Oxford, OX5 1GB, UK

**Registered Company**

**Number**

1982084

**Customer name** Nicole Regna

**Customer address** 1410 Prices Fork Rd.  
BLACKSBURG, VA 24061

**License number** 3410890468671

**License date** Jun 16, 2014

**Licensed content publisher** Elsevier

**Licensed content**

**publication**

Clinical Immunology

**Licensed content title** Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis *in vivo*

**Licensed content author** Nicole L. Regna, Cristen B. Chafin, Sarah E. Hammond, Abdul G. Puthiyaveetil, David L. Caudell, Christopher M. Reilly

**Licensed content date** March 2014

**Licensed content volume**  
**number**

151

**Licensed content issue**  
**number**

1

**Number of pages** 14

**Start Page** 29

**End Page** 42

**Type of Use** reuse in a thesis/dissertation

**Portion** full article

**Format** electronic

**Are you the author of this**

**Elsevier article?**

Yes

**Will you be translating?** No

**Title of your**  
**thesis/dissertation**

Isoform Selective HDAC Inhibition for the Treatment of Lupus Nephritis

**Expected completion date** Jun 2014

Estimated size (number of pages)

155

Elsevier VAT number GB 494 6272 12

Permissions price 0.00 USD

VAT/Local Sales Tax 0.00 USD / 0.00 GBP

Total 0.00 USD

[Terms and Conditions](#)

## INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

## GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter,

Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY

COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number,

Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier.”

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or

any other alterations shall be made only with prior written authorization of Elsevier Ltd.  
(Please

contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com))

6. If the permission fee for the requested use of our material is waived in this instance, please be

advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of

(i) the license details provided by you and accepted in the course of this licensing transaction, (ii)

6/16/2014 Rightslink Printable License

<https://s100.copyright.com/AppDispatchServlet> 3/7

these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon

issuance of the license at the end of the licensing process for the transaction, provided that you have

disclosed complete and accurate details of your proposed use, no license is finally effective unless

and until full payment is received from you (either by publisher or by CCC) as provided in CCC's

Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any

license preliminarily granted shall be deemed automatically revoked and shall be void as if never

granted. Further, in the event that you breach any of these terms and conditions or any of CCC's

Billing and Payment terms and conditions, the license is automatically revoked and shall be void as

if never granted. Use of materials as described in a revoked license, as well as any use of the

materials beyond the scope of an unrevoked license, may constitute copyright infringement and

publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their

respective officers, directors, employees and agents, from and against any and all claims arising out

of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned,

or transferred by you to any other person without publisher's written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed

by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase

order, acknowledgment, check endorsement or other writing prepared by you, which terms are

inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions.

These terms and conditions, together with CCC's Billing and Payment terms and conditions (which

are incorporated herein), comprise the entire agreement between you and publisher (and CCC)

concerning this licensing transaction. In the event of any conflict between your obligations

established by these terms and conditions and those established by CCC's Billing and Payment

terms and conditions, these terms and conditions shall control.

14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this

License at their sole discretion, for any reason or no reason, with a full refund payable to you.

Notice of such denial will be made using the contact information provided by you.

Failure to

receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright

Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a

result of a denial of your permission request, other than a refund of the amount(s) paid by you to

Elsevier and/or Copyright Clearance Center for denied permissions.

#### LIMITED LICENSE

The following terms and conditions apply only to specific license types:

6/16/2014 Rightslink Printable License

<https://s100.copyright.com/AppDispatchServlet> 4/7

15. Translation: This permission is granted for non-exclusive world English rights only unless

your license was granted for translation rights. If you licensed translation rights you may only

translate this content into the languages you requested. A professional translator must perform all

translations and reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all languages.

16. Posting licensed content on any Website: The following terms and conditions apply as

follows: Licensing material from an Elsevier journal: All content posted to the web site must

maintain the copyright information line on the bottom of each image; A hyper-text must be included

to the Homepage of the journal from which you are licensing at

<http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at

<http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned

version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier

homepage at <http://www.elsevier.com> . All content posted to the web site must maintain the

copyright information line on the bottom of each image.

Posting licensed content on Electronic reserve: In addition to the above the following clauses

are applicable: The web site must be password-protected and made available only to bona fide

students registered on a relevant course. This permission is granted for 1 year only. You may obtain

a new license for future website posting.

For journal authors: the following clauses are applicable in addition to the above:

Permission

granted is limited to the author accepted manuscript version\* of your paper.

\*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is

the author's version of the manuscript of an article that has been accepted for publication and which

may include any author-incorporated changes suggested through the processes of submission

processing, peer review, and editor-author communications. AAMs do not include other publisher

value-added contributions such as copy-editing, formatting, technical enhancements and (if

relevant) pagination.

You are not allowed to download and post the published journal article (whether PDF or HTML,

proof or final version), nor may you scan the printed edition to create an electronic version. A

hyper-text must be included to the Homepage of the journal from which you are licensing at

<http://www.sciencedirect.com/science/journal/xxxxx>. As part of our normal production process,

you will receive an e-mail notice when your article appears on Elsevier's online service ScienceDirect ([www.sciencedirect.com](http://www.sciencedirect.com)). That e-mail will include the article's Digital Object

Identifier (DOI). This number provides the electronic link to the published article and should be

included in the posting of your personal version. We ask that you wait until you receive this e-mail

and have the DOI to do any posting.

Posting to a repository: Authors may post their AAM immediately to their employer's institutional repository for internal use only and may make their manuscript publically available after

the journal-specific embargo period has ended.

6/16/2014 Rightslink Printable License

<https://s100.copyright.com/AppDispatchServlet> 5/7

Please also refer to [Elsevier's Article Posting Policy](#) for further information.

18. For book authors the following clauses are applicable in addition to the above:

Authors are

permitted to place a brief summary of their work online only.. You are not allowed to download

and post the published electronic version of your chapter, nor may you scan the printed edition to

create an electronic version. Posting to a repository: Authors are permitted to post a summary of

their chapter only in their institution's repository.

20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be

submitted to your institution in either print or electronic form. Should your thesis be published

commercially, please reapply for permission. These requirements include permission for the Library

and Archives of Canada to supply single copies, on demand, of the complete thesis and include

permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis

be published commercially, please reapply for permission.

## Elsevier Open Access Terms and Conditions

Elsevier publishes Open Access articles in both its Open Access journals and via its Open Access

articles option in subscription journals.

Authors publishing in an Open Access journal or who choose to make their article Open Access in

an Elsevier subscription journal select one of the following Creative Commons user licenses, which

define how a reader may reuse their work: Creative Commons Attribution License (CC BY),

Creative Commons Attribution – Non Commercial - ShareAlike (CC BY NC SA) and Creative

Commons Attribution – Non Commercial – No Derivatives (CC BY NC ND)

Terms & Conditions applicable to all Elsevier Open Access articles:

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor

should the article be modified in such a way as to damage the author's honour or reputation.

The author(s) must be appropriately credited.

If any part of the material to be used (for example, figures) has appeared in our publication with

credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse

complies with the terms and conditions determined by the rights holder.

Additional Terms & Conditions applicable to each Creative Commons user license:

CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised

versions, adaptations or derivative works of or from an article (such as a translation), to include in a

collective work (such as an anthology), to text or data mine the article, including for commercial

purposes without permission from Elsevier

CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create

extracts, abstracts and other revised versions, adaptations or derivative works of or from an article

6/16/2014 Rightslink Printable License

<https://s100.copyright.com/AppDispatchServlet> 6/7

(such as a translation), to include in a collective work (such as an anthology), to text and data mine

the article and license new adaptations or creations under identical terms without permission from

Elsevier

CC BY NC ND: For non-commercial purposes you may distribute and copy the article and

include it in a collective work (such as an anthology), provided you do not alter or modify the

article, without permission from Elsevier

Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC

ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Promotional purposes (advertising or marketing)
- Commercial exploitation ( e.g. a product for sale or loan)
- Systematic distribution (for a fee or free of charge)

Please refer to [Elsevier's Open Access Policy](#) for further information.

21. Other Conditions:

v1.7

If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number 501329387.

Once you receive your invoice for this order, you may pay your invoice by credit card.

Please follow instructions provided at that time.

Make Payment To:

Copyright Clearance Center

Dept 001

P.O. Box 843006

Boston, MA 02284-3006

For suggestions or comments regarding this order, contact RightsLink Customer Support: [customercare@copyright.com](mailto:customercare@copyright.com) or +1-877-622-5543 (toll free in the US) or +1-978-646-2777.

Gratis licenses (referencing \$0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.

6/16/2014 Rightslink Printable License

<https://s100.copyright.com/AppDispatchServlet 7/7>

# Journal of Clinical & Cellular Immunology

Open Access

ISSN: 2155-9899

[HOME](#) » [OPEN-ACCESS](#) » [ISOFORMSELECTIVE-HDAC-INHIBITION-IN-AUTOIMMUNE-DISEASE-2155-9899](#)

| [English](#)

[Review Article Open Access](#)

## Isoform-Selective HDAC Inhibition in Autoimmune Disease

Nicole L Regna<sup>1\*</sup> and Christopher M Reilly<sup>2</sup>

<sup>1</sup>Department of Biomedical Sciences & Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic

Institute and State University, Blacksburg, VA, 24061, USA

<sup>2</sup>Edward Via College of Osteopathic Medicine, Blacksburg, VA, 24060, USA

**Corresponding Author** : Nicole Regna

Center for Molecular Medicine and Infectious Diseases (CMMID)

Virginia-Maryland Regional College of Veterinary Medicine

1410 Prices Fork Road, Blacksburg, VA, 24061, USA

Tel: (434) 609-2703

Fax: (540) 231-3426

E-mail: [appleton@vt.edu](mailto:appleton@vt.edu)

**Received** March 04, 2014; **Accepted** April 07, 2014; **Published** April 14, 2014

**Citation:** Regna NL, Reillya CM (2014) Isoform-Selective HDAC Inhibition in Autoimmune Disease. J Clin Cell Immunol 5:207. doi:

10.4172/2155-9899.1000207

**Copyright:** © 2014 Regna NL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution

License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

[Related article at](#)

[Pubmed Scholar Google](#)

[Visit for more related articles at](#)

[Journal of Clinical & Cellular Immunology](#)

[Select your language of interest to](#)

[view the total content in your](#)

[interested language](#)

**Select Language**

Powered by Translate

## Share This Article

### About JCCI

[Journal Home](#)

[Editorial Board Members](#)

[Current Issue](#)

[Previous Issue](#)

[Archive](#)

[Instructions for Authors](#)

[Submit Manuscript](#)

[Contact Editorial Office](#)

### Article usage

Total views: **1025**

[From(publication date):  
April-2014- Jun 16, 2014]

Breakdown by view type

HTML page views : **246**

PDF downloads : **779**

### Article Tools

[Export citation](#)

[Share/Blog this article](#)

[Recommend to your Librarian](#)

### Special Features

[Download PDF](#)

[Digital File](#)

[Listen Audio](#)

[Download Audio](#)

[SharSeharSeharSeharSeharSeharSehare](#)

[SharSeharSeharSeharMeore](#)

[Abstract Full Text Tables at a glance PDF](#)